ArticleCureus2025
Recurrent Ischaemic Stroke in a Patient With Left Ventricular Thrombus Despite Apixaban: Successful Transition to Warfarin.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular (LV) thrombus is a well-recognised source of cardioembolic stroke, especially in patients with severely reduced LV ejection fraction (LVEF). Anticoagulation is the mainstay of therapy, but the optimal agent remains debated. We report the case of a 68-year-old man with an LV thrombus who suffered recurrent ischemic strokes while on apixaban, with magnetic resonance imaging (MRI) of the brain demonstrating acute infarcts in the left thalamocapsular and occipitotemporal regions. Following multidisciplinary team review, he was transitioned to warfarin with low-molecular-weight heparin (LMWH) bridging, after which he achieved therapeutic international normalised ratio (INR) stability and experienced no further clinically apparent embolic events. This case underscores the ongoing embolic risk associated with LV thrombus despite direct oral anticoagulant (DOAC) therapy, the importance of LMWH bridging when initiating warfarin, and the value of multidisciplinary management in optimising outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.